Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051228 | 0.92 | GPR119 (0.50) | GPR119HPGD | |
| SCHEMBL13274147 | 0.91 | GPR119 (0.65) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL8018 | 0.90 | HPGD (0.58) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL310117 | 0.89 | GPR119 (0.67) | GPR119HPGDRECQLEPHX1 | |
| Hydrochloric Acid SCHEMBL307023 | 0.88 | HPGD (0.57) | GPR119HPGDRECQLEPHX1KDM4E | |
| Acetic Acid SCHEMBL6198968 | 0.85 | HPGD (0.54) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL22284263 | 0.85 | GPR119 (0.58) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL21359212 | 0.84 | EPHX1 (0.62) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL24582050 | 0.83 | GPR119 (0.57) | GPR119HPGDRECQLEPHX1PTPN2 | |
| SCHEMBL328895 | 0.83 | HPGD (0.60) | GPR119HPGDRECQLEPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454257-B1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2454257-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | GPR119 3853/4885HPGD 3126/4885RECQL 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.